Menu
Recruiting NCT06880809

Bridge the Gap (BTG) - Black Youth Group

No phase Interventional Suicide Prevention

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Bridge the Gap (BTG) - Black Youth Group.
Who it may be relevant to
Registry conditions: Suicide Prevention. Basic parameters: 12 years — 17 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Bridging the Gap: A Collaborative Intervention Group for Black Youth at Risk for Suicide

Overview

The goal of this clinical trial is to develop and preliminarily test a culturally adapted suicide intervention specifically for black youth. The main question it aims to answer: -To evaluate the feasibility and acceptability of the group, as well as the preliminary efficacy of the group for decreasing suicidal thoughts and behaviors and increasing protective factors such as hope, positive ethnic identity, and family and peer support. Participants will be asked to attend 10-week group intervention and complete pre-treatment and post-treatment assessment measures.

Interventions

  • Behavioral Bridge the Gap (BTG) - Black Youth Group
    Participants will complete a group intervention, rooted in the Collaborative Assessment \& Management of Suicidality (CAMS) evidence-based model, driven by their own unique identification of suicide drivers.

Primary outcome measures

  • The Collaborative Assessment & Management of Suicidality - Suicide Status Form (SSF) [Time frame: From pre-treatment until 3 months post-treatment, approximately 23 weeks.]
  • Ethnic Identity Scale (EIS) [Time frame: From baseline until 3 months post-treatment, approximately 22 weeks.]
  • Living Ladder Scale [Time frame: From baseline until 3 months post-treatment, approximately 22 weeks.]
  • Brief Suicide Cognitions Scale (B-SCS) [Time frame: From baseline until 3 months post-treatment, approximately 22 weeks.]
  • Therapeutic Relationship Working Alliance Inventory, Short Revised (WAI-SR) [Time frame: From baseline until 3 months post-treatment, approximately 22 weeks.]
  • Optimism and Hope Scale (OHS) [Time frame: From baseline until 3 months post-treatment, approximately 22 weeks.]
  • Parent Readiness for Hospital Discharge Scale (RHDS) [Time frame: From baseline until 3 months post-treatment, approximately 22 weeks.]
  • Group Cohesion Scale [Time frame: From baseline until the beginning of post-treatment, approximately 10 weeks.]

Eligibility criteria

Inclusion criteria

  • 12-17 years old
  • Identify as Black or African American or being of African descent
  • Have current suicidal ideation or suicidal ideation within the last 30 days
  • Have assent from the adolescent participant and consent from an individual's caregiver or guardian to participate.

Exclusion criteria

  • An active psychotic disorder or current psychosis symptoms
  • No history of suicide attempt(s) or suicide ideation in the past 30 days
  • Cognitive deficits or a medical condition diagnosed from a medical provider that precludes full understanding of study materials as assessed through an inability to complete the pre-treatment CAMS SSF \& SSP
  • Caregivers, guardians, and/or the patient refuse to participate.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Prevention

Study locations

United States · 1 center
  • Children's Hospital Los Angeles — Los Angeles

Identifiers

NCT: NCT06880809 · CHLA-25-00072

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗